CN116723837A - Cdk2抑制剂的固体形式 - Google Patents

Cdk2抑制剂的固体形式 Download PDF

Info

Publication number
CN116723837A
CN116723837A CN202180086069.9A CN202180086069A CN116723837A CN 116723837 A CN116723837 A CN 116723837A CN 202180086069 A CN202180086069 A CN 202180086069A CN 116723837 A CN116723837 A CN 116723837A
Authority
CN
China
Prior art keywords
cancer
ppm
crystalline
values
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180086069.9A
Other languages
English (en)
Chinese (zh)
Inventor
F·曹
K·F·德布亚赛
M·希伯来茵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN116723837A publication Critical patent/CN116723837A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cereal-Derived Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180086069.9A 2020-12-24 2021-12-21 Cdk2抑制剂的固体形式 Pending CN116723837A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063130530P 2020-12-24 2020-12-24
US63/130,530 2020-12-24
PCT/IB2021/062082 WO2022137106A1 (en) 2020-12-24 2021-12-21 Solid forms of a cdk2 inhibitor

Publications (1)

Publication Number Publication Date
CN116723837A true CN116723837A (zh) 2023-09-08

Family

ID=79283019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180086069.9A Pending CN116723837A (zh) 2020-12-24 2021-12-21 Cdk2抑制剂的固体形式

Country Status (10)

Country Link
US (1) US20240076287A1 (https=)
EP (1) EP4267563A1 (https=)
JP (1) JP2024503235A (https=)
KR (1) KR20230122100A (https=)
CN (1) CN116723837A (https=)
AU (1) AU2021404974B2 (https=)
CA (1) CA3206153A1 (https=)
MX (1) MX2023007699A (https=)
TW (1) TWI823213B (https=)
WO (1) WO2022137106A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
US20250127759A1 (en) * 2021-12-02 2025-04-24 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
US20250195475A1 (en) * 2022-01-27 2025-06-19 InventisBio Co., Ltd. Cdk2 inhibitor and preparation method and use thereof
WO2024046443A1 (en) * 2022-09-01 2024-03-07 Nutshell Biotech (Shanghai) Co., Ltd. Macrocyclic compounds as selective cdk inhibitors
WO2025191482A1 (en) 2024-03-15 2025-09-18 Pfizer Inc. Synthesis of (1h-pyrazol-5-yl)cyclopentyl carbamate compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157652A2 (en) * 2019-01-31 2020-08-06 Pfizer Inc. Cdk2 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157652A2 (en) * 2019-01-31 2020-08-06 Pfizer Inc. Cdk2 inhibitors

Also Published As

Publication number Publication date
JP2024503235A (ja) 2024-01-25
CA3206153A1 (en) 2022-06-30
MX2023007699A (es) 2023-07-10
AU2021404974A9 (en) 2025-04-10
WO2022137106A1 (en) 2022-06-30
KR20230122100A (ko) 2023-08-22
US20240076287A1 (en) 2024-03-07
TWI823213B (zh) 2023-11-21
AU2021404974B2 (en) 2024-11-28
TW202233606A (zh) 2022-09-01
EP4267563A1 (en) 2023-11-01
AU2021404974A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
CN116507620B (zh) Cdk4抑制剂的固体形式
TWI823213B (zh) Cdk2抑制劑之固體形式
US12152034B2 (en) FGFR inhibitors and methods of making and using the same
UA125025C2 (uk) Способи лікування дитячих ракових захворювань
CN117337293A (zh) 固体形式的eif4e抑制剂
KR20240145475A (ko) 고형 종양의 치료를 위한 유비퀴틴-특이적-프로세싱 프로테아제 1 (usp1) 억제제
TW202340215A (zh) Ｆｇｆｒ抑制劑之鹽及固體形式以及其製備方法
JP2025540560A (ja) Ｅｇｆｒ阻害剤のフマル酸塩、酒石酸塩、リンゴ酸塩、及びクエン酸塩
TW202115091A (zh) 喹啉類似物之結晶型及其鹽類、組合物、及彼等之使用方法
RU2856216C1 (ru) Твердые формы ингибитора cdk4
RU2850825C1 (ru) Твердые формы ингибитора cdk2
CA3195063C (en) Solid forms of the cdk4 inhibitor pf-07220060
HK40096368A (zh) Cdk2抑制剂的固体形式
HK40087859A (zh) Cdk4抑制剂的固体形式
BR112023004713B1 (pt) Formas sólidas de um inibidor de cdk4 e sua composição farmacêutica
HK40125945A (zh) Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐
EA049394B1 (ru) Ингибиторы fgfr и способы их получения и применения
CN108025009A (zh) 喹喔啉基-哌嗪酰胺的使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096368

Country of ref document: HK